UBS lowered the firm’s price target on Select Medical (SEM) to $21 from $40 and keeps a Neutral rating on the shares following the completion of the spinoff of Concentra (CON). Following the completion of the spin, Select Medical no longer owns any shares of Concentra common stock, the analyst tells investors in a research note.